Role of Delta-aminolevulinic Acid in the Symptoms of Acute Porphyria
- 7 November 2014
- journal article
- research article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 128 (3), 313-317
- https://doi.org/10.1016/j.amjmed.2014.10.026
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Liver transplantation in the management of porphyriaHepatology, 2014
- Lead poisoning in pregnant women who used Ayurvedic medications from India--New York City, 2011-2012.2012
- Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the InternetJAMA, 2008
- Recommendations for Medical Management of Adult Lead ExposureEnvironmental Health Perspectives, 2007
- Safety, Pharmacokinetics and Pharmocodynamics of Recombinant Human Porphobilinogen Deaminase in Healthy Subjects and Asymptomatic Carriers of the Acute Intermittent Porphyria Gene Who Have Increased Porphyrin Precursor ExcretionClinical Pharmacokinetics, 2007
- Recommendations for the Diagnosis and Treatment of the Acute PorphyriasAnnals of Internal Medicine, 2005
- Clinical and Biochemical Characteristics and Genotype-Phenotype Correlation in 143 Finnish and Russian Patients With Acute Intermittent PorphyriaMedicine, 2005
- Hematin therapy for the neurologic crisis of tyrosinemiaThe Journal of Pediatrics, 1991
- Treatment of acute hepatic porphyria with hematinJournal of Hepatology, 1988
- Hereditary Tyrosinemia and the Heme Biosynthetic Pathway. PROFOUND INHIBITION OF δ-AMINOLEVULINIC ACID DEHYDRATASE ACTIVITY BY SUCCINYLACETONEJCI Insight, 1983